Transforming Psychiatric Care: From Psilocybin Breakthroughs to Scalable, Multi-Indication Therapeutics
- Detailing Phase 3 successes of COMP360 psilocybin in treatment resistant depression, including rapid onset, durability to 26 weeks, and FDA submission readiness
- Examining early signal-generation studies exploring COMP360’s potential in PTSD
- Exploring retreatment protocols to optimize patient stratification, dosing, and long-term efficacy
- Discussing operational strategies, including site selection, regulatory engagement, and scalability, to drive commercial readiness and global deployment